Provided by Tiger Fintech (Singapore) Pte. Ltd.

LAVA Therapeutics N.V.

1.31
0.0000
Post-market: 1.30-0.0100-0.76%16:38 EDT
Volume:6.99K
Turnover:9.20K
Market Cap:34.46M
PE:-1.26
High:1.32
Open:1.31
Low:1.31
Close:1.31
Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
17 Mar

LAVA Therapeutics NV expected to post a loss of 29 cents a share - Earnings Preview

Reuters
·
14 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

BRIEF-LAVA Therapeutics NV Receives Nasdaq Non-Compliance Notice For Minimum Bid Price

Reuters
·
01 Mar

LAVA Therapeutics Nv - Receives Nasdaq Non-Compliance Notice for Minimum Bid Price

THOMSON REUTERS
·
01 Mar

Lava Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
27 Feb

LAVA Therapeutics Nv : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
27 Feb

HC Wainwright Downgrades LAVA Therapeutics to Neutral From Buy, Adjusts Price Target to $1.50 From $2

MT Newswires Live
·
27 Feb

LAVA Therapeutics N.v. : H.c. Wainwright Cuts Target Price to $1.5 From $2

THOMSON REUTERS
·
27 Feb

BUZZ-LAVA Therapeutics jumps on merger or sale talks, cuts 30% of jobs

Reuters
·
25 Feb

Lava Therapeutics announces evaluation of strategic options

TIPRANKS
·
25 Feb

LAVA Therapeutics Nv - Implements Workforce Reduction of Approximately 30%

THOMSON REUTERS
·
25 Feb

LAVA Therapeutics Nv - to Explore Diverse Strategic Options Including Sale or Merger

THOMSON REUTERS
·
25 Feb

LAVA Therapeutics Nv - Initiates Strategic Review and Implements Workforce Reduction

THOMSON REUTERS
·
25 Feb

LAVA Announces Evaluation of Strategic Options

THOMSON REUTERS
·
25 Feb

LAVA Announces Evaluation of Strategic Options

GlobeNewswire
·
25 Feb

BRIEF-LAVA Doses First Patient In Phase 1 LAVA-1266 Study In Hematological Cancers

Reuters
·
10 Jan

LAVA Therapeutics Nv: Initial Phase 1 Data Read-Out Expected by Year-End 2025

THOMSON REUTERS
·
10 Jan

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

THOMSON REUTERS
·
10 Jan

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

GlobeNewswire
·
10 Jan